Debiopharm International SA - Articles and news items

Debiopharm’s triptorelin 6-month formulation receives EU approval

Industry news / 20 March 2017 / Niamh Marriott, Junior Editor

Debiopharm International, a Swiss-based company, part of Debiopharm Group, announced that triptorelin 6-month formulation (Decapeptyl and Pamorelin 22.5 mg) received approval for the treatment of central precocious puberty (CPP) in 22 European countries, where the 6-month formulation has already been registered for the treatment of prostate cancer. Triptorelin is the first 6-month GnRH agonist formulation […]

EMA grants Orphan Drug Designation for Debio 1143

Industry news / 8 December 2015 / Victoria White

Debio1143 is an oral, small molecule inhibitor of IAPs with a dual pro-apoptotic and immunomodulatory mode of action developed as a potent chemo/radiosensitiser in ovarian cancer…

Debiopharm announces positive Phase III results for triptorelin 6-month formulation in the management of central precocious puberty

Industry news / 19 May 2015 / Victoria White

Debiopharm has announced the completion of a Phase III study with triptorelin 6-month formulation in 44 patients with central precocious puberty…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+